SCHEMBL24491208

SCHEMBL24491208

Cc1ccc(COC(=O)N(C)CC(N)=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRSS1 P07477 1/20 0.53
▸ TPSAB1 Q15661 1/20 0.53
▸ PARP10 Q53GL7 1/20 0.44
▸ RAB9A P51151 4/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ MMP2 P08253 2/20 0.43
▸ MMP12 P39900 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ AGXT P21549 2/20 0.42
▸ MMP1 P03956 1/20 0.40
▸ MMP9 P14780 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ ALDH1A1 P00352 4/20 0.39
▸ MAPT P10636 2/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ P2RX4 Q99571 1/20 0.39
▸ MAOB P27338 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15601806 0.86 PRSS1 (0.51) PRSS1TPSAB1RAB9ANPC1MMP2
SCHEMBL5331588 0.86 ALDH1A1 (0.51) PRSS1TPSAB1ALDH1A1MAPTMAPK1
SCHEMBL24062673 0.82 PRSS1 (0.47) PRSS1TPSAB1PARP10RAB9ANPC1
SCHEMBL11131589 0.80 MMP2 (0.49) PRSS1TPSAB1PARP10RAB9ANPC1
SCHEMBL24591903 0.79 MMP2 (0.47) PRSS1TPSAB1PARP10RAB9ANPC1
SCHEMBL23488765 0.78 PRSS1 (0.44) PRSS1TPSAB1PARP10RAB9ANPC1
SCHEMBL21348175 0.78 PRSS1 (0.44) PRSS1TPSAB1PARP10RAB9ANPC1
SCHEMBL25962335 0.76 PRSS1 (0.42) PRSS1TPSAB1PARP10RAB9ANPC1
SCHEMBL2297635 0.76 PARP10 (0.54) PARP10RAB9ANPC1MMP2MMP12
SCHEMBL20630435 0.75 PRSS1 (0.53) PRSS1TPSAB1CYP1A2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220175761-A1 BI-LIGAND DRUG CONJUGATE AND USE THEREOF COHERENT BIOPHARMA SUZHOU LTD (CN) 2022-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220175761-A1 BI-LIGAND DRUG CONJUGATE AND USE THEREOF SLC10A1, CD47, SELPLG PRSS1 3754/4885TPSAB1 3951/4885PARP10 1308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback